Literature DB >> 7672047

Syphilis serology among transvestite prostitutes attending an HIV unit in Rome, Italy.

P Gattari1, D Speziale, R Grillo, P Cattani, M Zaccarelli, L Spizzichino, C Valenzi.   

Abstract

Sixty-seven transvestite prostitutes from Latin America (49 from Brazil and 18 from Colombia) who attended an HIV unit located in the inner city of Rome between January 1991 and June 1992 were studied for syphilis markers by means of both the Treponema pallidum haemoagglutination test (TPHA) and a solid phase haemadsorption test for detection of specific IgM (SPHA-IgM) which are typically present in recent infections. All participants reported more than 500 sexual partners in the past year, and 67.1% of them more than 1500 partners (between 5 and 10 partners per working day). The overall prevalence of anti-HIV antibodies in this population was 65.7%. The prevalence of positive TPHA tests in the population studied was 73.1%, while that of positive SPHA-IgM tests was 10.4%. The prevalence of positive TPHA and SPHA-IgM tests was higher among Columbians than among Brazilians (83.3% vs 69.4% and 22.2% vs 6.1%, respectively) and also showed a positive correlation with the duration of their permanence in Italy. The TPHA and SPHA-IgM positivities were significantly higher among subjects older than 29 years. Positive TPHA was also significantly higher in subjects who reported a history of heroin and/or cocaine abuse while positive SPHA-IgM was higher in subjects who did not use condoms or reported irregular use of them than in subjects who regularly used condoms. No overall correlation was evident between TPHA positivity and anti-HIV positivity, while SPHA-IgM positivity was found to be higher among anti-HIV-negative subjects.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7672047     DOI: 10.1007/bf01719281

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  14 in total

Review 1.  Syphilis: new diagnostic directions.

Authors:  H Young
Journal:  Int J STD AIDS       Date:  1992 Nov-Dec       Impact factor: 1.359

2.  Primary and secondary syphilis--United States, 1981-1990.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1991-05-17       Impact factor: 17.586

3.  Specific syphilis serological tests may become negative in HIV infection.

Authors:  P D Johnson; S R Graves; L Stewart; R Warren; B Dwyer; C R Lucas
Journal:  AIDS       Date:  1991-04       Impact factor: 4.177

4.  Epidemiology of primary and secondary syphilis in the United States, 1981 through 1989.

Authors:  R T Rolfs; A K Nakashima
Journal:  JAMA       Date:  1990-09-19       Impact factor: 56.272

5.  Importance of specific IgM antibodies in 116 patients with various stages of syphilis.

Authors:  S Merlin; J Andre; B Alacoque; A Paris-Hamelin
Journal:  Genitourin Med       Date:  1985-04

6.  Risk factors for human immunodeficiency virus (HIV) infections in homosexual men.

Authors:  W W Darrow; D F Echenberg; H W Jaffe; P M O'Malley; R H Byers; J P Getchell; J W Curran
Journal:  Am J Public Health       Date:  1987-04       Impact factor: 9.308

7.  Seronegative secondary syphilis in a patient infected with the human immunodeficiency virus (HIV) with Kaposi sarcoma. A diagnostic dilemma.

Authors:  C B Hicks; P M Benson; G P Lupton; E C Tramont
Journal:  Ann Intern Med       Date:  1987-10       Impact factor: 25.391

8.  Solid-hase hemadsorption: a method for rapid detection of Treponema pallidum-specific IgM.

Authors:  B L Schmidt
Journal:  Sex Transm Dis       Date:  1980 Apr-Jun       Impact factor: 2.830

9.  Laboratory diagnosis of congenital syphilis by immunoglobulin M (IgM) and IgA immunoblotting.

Authors:  J L Schmitz; K S Gertis; C Mauney; L V Stamm; J D Folds
Journal:  Clin Diagn Lab Immunol       Date:  1994-01

Review 10.  Biologic factors in the sexual transmission of human immunodeficiency virus.

Authors:  S D Holmberg; C R Horsburgh; J W Ward; H W Jaffe
Journal:  J Infect Dis       Date:  1989-07       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.